<DOC>
	<DOCNO>NCT00405457</DOCNO>
	<brief_summary>To evaluate efficacy , safety tolerability combination Optive® Artificial Tears Restasis®.The primary hypothesis Ocular Surface Disease Index ( OSDI ) score symptom low baseline treatment patient . The patient tolerate combination Restasis® Optive® low incidence clinical adverse event .</brief_summary>
	<brief_title>Efficacy Safety New Multi-dose Lubricant Eye Drop Concomitant With Restasis® ( Cyclosporine A ) Treatment Dry Eye Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<criteria>· Males female &gt; 18 year old Patients currently take Restasis® least 3 month duration use artificial tear need dry eye . Likely complete study visit able provide inform consent · Patients use Restasis® le 3 month . Known contraindication study medication ingredient Female child bear potential use reliable method birth control , pregnant lactating female . Other active uncontrolled ocular disease uncontrolled systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>